AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22832260
Drug: Bivalent rLP2086
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent rLP2086 vaccine (60, 120, or 200 μg)
Trial: 22832260
Drug: Bivalent rLP2086
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent rLP2086 vaccine
Trial: 12948311
Drug: 0.5% piroxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% piroxicam ophthalmic solution
Trial: 12948311
Drug: 0.1% diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% diclofenac sodium ophthalmic solution
Trial: 8831918
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ciprofibrate/day
Trial: 8831918
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ciprofibrate/day
Trial: 8831918
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg fenofibrate HB/day
Trial: 1403397
Drug: Dexamethasone, 0.25
RxNorm normalized name: Dexamethasone, 0.25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone, 0.25 mg/kg per dose, every 8 hours for a total of three doses
Trial: 4059871
Drug: Tobramycin injections
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin injections every 8 hours (TID) for 4 days followed by every 12 hours (BID)
Trial: 4059871
Drug: Tobramycin injections
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin injections every 12 hours (BID) for 4 days followed by every 8 hours (TID)
Trial: 2979067
Drug: Morphine sulfate,
RxNorm normalized name: Morphine Sulfate, 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine sulfate, 5 to 10 mg IV
Trial: 2979067
Drug: Meperidine, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine, 25 to 50 mg IV
Trial: 27888575
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen concentrate (2 g infusion)
Trial: 25500574
Drug: Rectal diazepam
RxNorm normalized name: diazepam Rectal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diazepam (0.5 mg/kg)
Trial: 23040523
Drug: 7.5 g
RxNorm normalized name: glucose 15 GM per 37.5 GM Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 g T gel daily (75 mg delivered)
Trial: 19087606
Drug: Yunnan Baiyao
RxNorm normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yunnan Baiyao capsules (prophylactic oral administration for 3 days before operation)
Trial: 19087606
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no Yunnan Baiyao administration)
Trial: 16491236
Drug: Fibroblasts from
RxNorm normalized name: Foreskin fibroblast (neonatal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibroblasts from normal Tenon capsule
Trial: 3511933
Drug: Phenobarbitone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone (50 mg for 10 days)
Trial: 3511933
Drug: Flumecinol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumecinol (200 mg and 600 mg for 6 days)
Trial: 3511933
Drug: Cimetidine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (600 mg for 6 days)
Trial: 27439969
Drug: Distal colonic
RxNorm normalized name: colonial bent grass pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal colonic acetate infusion (180 mmol/l)
Trial: 27439969
Drug: Distal colonic
RxNorm normalized name: colonial bent grass pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal colonic acetate infusion (100 mmol/l)
Trial: 27439969
Drug: Proximal colonic
RxNorm normalized name: colonial bent grass pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proximal colonic acetate infusion
Trial: 30220293
Drug: Newly developed
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly developed generic formulation of abiraterone acetate (250 mg)
Trial: 30220293
Drug: Branded formulation
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded formulation of abiraterone acetate (Zytiga, 250 mg)
Trial: 2405727
Drug: Meglumine antimonate
RxNorm normalized name: meglumine antimonate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine antimonate (Glucantime), 850 mg antimony/day im for 15 days
Trial: 2405727
Drug: Localized controlled
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Localized controlled heat, 50 degrees C for 30 sec, 3 treatments at 7 day intervals
Trial: 6990946
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg diazepam every six hours for 48 hours
Trial: 22742578
Drug: Paracetamol 4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 4000 mg q.d.s.
Trial: 22742578
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg q.d.s.
Trial: 22742578
Drug: Paracetamol 4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 4000 mg q.d.s. and Aspirin 325 mg q.d.s.
Trial: 20378868
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate infusion
Trial: 17356283
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for comorbid anxiety disorder
Trial: 17356283
Drug: Alcohol treatment
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol treatment alone
Trial: 7865625
Drug: Anti-tumour-associated glycoprotein
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tumour-associated glycoprotein 72 antibody B72.3
Trial: 24829088
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml glucose drink (200 kcal)
Trial: 24829088
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion at 4 kcal/min into the proximal Roux-limb
Trial: 24829088
Drug: 4 kcal/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 kcal/min duodenal infusion (control group)
Trial: 22689678
Drug: Post‐consolidation immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post‐consolidation immunotherapy with histamine dihydrochloride and interleukin‐2
Trial: 22689678
Drug: Histamine H(2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine H(2) receptor expression
Trial: 16087995
Drug: 8 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g/d of a mixed short and long degree of polymerization inulin-type fructan product (fructan group)
Trial: 9036741
Drug: Heparin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin for ≤ 48 hours (group 1)
Trial: 9036741
Drug: Heparin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin for > 48 hours (group 2)
Trial: 1677818
Drug: Atracurium (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.3 mg/kg for <10 kg, 0.5 mg/kg for >10 kg)
Trial: 1677818
Drug: Vecuronium (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.05 mg/kg for <10 kg, 0.1 mg/kg for >10 kg)
Trial: 7011037
Drug: Debridement and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debridement and 3% acyclovir ointment
Trial: 24793535
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of rhPTH(1‐34) (10, 20, 30, 40, 50, or 60 μg)
Trial: 24793535
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of rhPTH(1‐34) (10 and 20 μg once daily for 7 consecutive days)
Trial: 24793535
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of rhPTH(1‐34) (10, 20, or 40 μg)
Trial: 24793535
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of rhPTH(1‐34) (20 μg)
Trial: 22551909
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/d plus OAT with warfarin (C + OAT)
Trial: 22551909
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy with clopidogrel 75 mg/d plus aspirin 100 mg/d (C + ASA)
Trial: 15457467
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg twice a day (n = 104)
Trial: 11404671
Drug: ORAL (0.45%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORAL (0.45% NaCl) equal to 50% of prior dehydration
Trial: 10791876
Drug: AIDSVAX (MN)
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIDSVAX (MN) vaccine (300 microg of MN-rgp120 in alum)
Trial: 7598995
Drug: Amoxicillin (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (control group) for 4 weeks
Trial: 306010
Drug: Whole gut
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole gut irrigation (w.g.i.)
Trial: 306010
Drug: Whole gut
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole gut irrigation (w.g.i.) for removal of blood from the intestinal tract
Trial: 31686817
Drug: Optimized DPX-loaded
RxNorm normalized name: DPX-Survivac
DrugBank: Maveropepimut-S (DB17339)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized DPX-loaded nanoparticles (30 mg single oral dose)
Trial: 31686817
Drug: Marketed DPX
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed DPX tablet
Trial: 15531304
Drug: Topical ocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular hypotensive medication (nonselective beta-blocker or prostaglandin analog)
Trial: 10093291
Drug: Bivalent Hib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent Hib and hepatitis B vaccine (7.5 micrograms of PRP bound to 125 micrograms of OMP and 5 micrograms of recombinant hepatitis B surface antigen)
Trial: 9631980
Drug: benazepril 20
RxNorm normalized name: benazepril 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril 20 to 40 mg/day
Trial: 2667601
Drug: Spiramycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiramycin (3 X 10(6) iu, twice daily)
Trial: 770082
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg azapropazone per day
Trial: 31286158
Drug: Electrotherapy, manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrotherapy, manual therapy, and pelvic floor muscle exercises
Trial: 21752899
Drug: Pioglitazone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (45 mg/d for 6 weeks)
Trial: 17144779
Drug: Various strategies
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various strategies for minimizing NSAID risks including low dosages, modified-release and enteric-coated NSAIDs, cyclooxygenase-2-selective inhibitors, monitoring for side effects, and treatments to minimize side effects.
Trial: 9107443
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR monotherapy 120 mg
Trial: 9107443
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR monotherapy 180 mg
Trial: 9107443
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR monotherapy 240 mg
Trial: 9107443
Drug: Trandolapril monotherapy
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trandolapril monotherapy 0.5 mg
Trial: 9107443
Drug: Trandolapril monotherapy
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trandolapril monotherapy 2 mg
Trial: 9107443
Drug: Trandolapril monotherapy
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trandolapril monotherapy 8 mg
Trial: 9231890
Drug: Trandolapril/Verapamil SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril/Verapamil SR combination 0.5/120 mg
Trial: 9231890
Drug: Trandolapril/Verapamil SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril/Verapamil SR combination 0.5/180 mg
Trial: 9231890
Drug: Trandolapril/Verapamil SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril/Verapamil SR combination 0.5/240 mg
Trial: 9231890
Drug: Trandolapril/Verapamil SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril/Verapamil SR combination 2/120 mg
Trial: 9231890
Drug: Trandolapril/Verapamil SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril/Verapamil SR combination 2/180 mg
Trial: 9231890
Drug: Trandolapril/Verapamil SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril/Verapamil SR combination 2/240 mg
Trial: 9231890
Drug: Trandolapril/Verapamil SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril/Verapamil SR combination 8/120 mg
Trial: 9231890
Drug: Trandolapril/Verapamil SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril/Verapamil SR combination 8/180 mg
Trial: 9231890
Drug: Trandolapril/Verapamil SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril/Verapamil SR combination 8/240 mg
Trial: 9231890
Drug: Mono- and
RxNorm normalized name: Mono- and Di-Glycerides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mono- and combination therapy
Trial: 7965901
Drug: Fluconazole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (50 mg once a day for 2 weeks)
Trial: 7965901
Drug: Fluconazole plus
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole plus chlorhexidine (chlorhexidine applied twice a day for 2 weeks)
Trial: 7965901
Drug: New dentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New dentures (no medication)
Trial: 3283085
Drug: Mixed-beam radiotherapy
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed-beam radiotherapy (2 fractions a week of neutrons, 3 fractions a week of photons to a total RBE-adjusted dose of 50 Gy over 5 weeks plus intracavitary applications or external mixed-beam boost)
Trial: 29043411
Drug: T‐DM1 (ado-trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T‐DM1 (ado-trastuzumab emtansine) administered weekly or every three weeks
Trial: 16843170
Drug: Rheolytic thrombectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheolytic thrombectomy (RT) as an adjunct to primary percutaneous coronary intervention (PCI)
Trial: 15931325
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors in postmenopausal women with invasive or intraductal breast cancer
Trial: 15931325
Drug: Targeted molecular
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Targeted molecular therapies such as trastuzumab and bisphosphonates
Trial: 27003390
Drug: Behavioral activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral activation program conducted weekly for 5 weeks in 60-min sessions
Trial: 19637333
Drug: EcN plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcN plus mesalamine (1500 mg twice a day)
Trial: 12852099
Drug: Oral continuous‐combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral continuous‐combined regimen of conjugated estrogens + medroxyprogesterone acetate
Trial: 8598355
Drug: ERT +
RxNorm normalized name: Enzyme Replacement Therapy Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERT + Mito (IV 12.5 mg/m(2) during the first and fourth week of ERT)
Trial: 8598355
Drug: BCNU (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCNU (i.v. 200 mg/m(2) every 6 weeks)
Trial: 8598355
Drug: 6-mercaptopurine (6-MP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine (6-MP, 750 mg/m(2) IV daily for 3 days every six weeks)
Trial: 6372066
Drug: Trimipramine, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimipramine, 50 mg/day
Trial: 23092239
Drug: L. plantarum
RxNorm normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. plantarum 299v
Trial: 23092239
Drug: Probiotic lactobacilli
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic lactobacilli lozenges (L. reuteri DSM 17938 and ATCC PTA 5289)
Trial: 23092239
Drug: Test group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test group (probiotic lozenges)
Trial: 17240231
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate 40 mg vaginally
Trial: 15701249
Drug: Paromomycin ointment
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin ointment (15%) applied twice daily for 30 days
Trial: 15701249
Drug: Placebo (10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10% urea lotion) applied twice daily for 30 days
Trial: 12088953
Drug: Ketamine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (1.0 mg/kg) with propofol and fentanyl (Group A)
Trial: 8951252
Drug: High-frequency oscillatory
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency oscillatory ventilation (HFOV) after surfactant administration (100 mg/kg)
Trial: 27777261
Drug: Exenatide infusion
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide infusion (n=29)
Trial: 21740575
Drug: Daily breakfast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily breakfast consumption (≥3000 kJ before 1100 each day)
Trial: 12954579
Drug: Ibandronate 6
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 6 mg
Trial: 9382122
Drug: Ibandronate 2
RxNorm normalized name: ibandronate 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 2 mg
Trial: 9192194
Drug: Mixed load
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed load (glucose+cream)
Trial: 9192194
Drug: Lipids load
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipids load (cream)
Trial: 28721080
Drug: Broad-spectrum antibiotic
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum antibiotic therapy
Trial: 28086005
Drug: Supportive-expressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive therapy
Trial: 24859124
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment (Control group, n=20)
Trial: 19082228
Drug: 2% tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% tea lotion
Trial: 19082228
Drug: 5% zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% zinc sulphate solution
Trial: 15930209
Drug: Morphine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (loading dose of 100 microg/kg, followed by infusions of 10-30 microg/kg per hour)
Trial: 15930209
Drug: Placebo (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5% dextrose infusions)
Trial: 12931804
Drug: Extracorporeal shock-wave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock-wave therapy
Trial: 8967584
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (18 mg/kg.h) with fentanyl (0.15 mg)
Trial: 8967584
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (18 mg/kg.h) without fentanyl
Trial: 8967584
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (18 mg/kg.h)
Trial: 1346599
Drug: Thioridazine tablet
RxNorm normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thioridazine tablet (5 mg), taken 1 hour after dinner from the 8th to the 18th day of the menstrual cycle.
Trial: 6206318
Drug: Digoxin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.25 to 1.0 mg/day)